Top Business

Trend About Business

iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday’s Pre-Market Session – Absci (NASDAQ:ABSI), Amazon.com (NASDAQ:AMZN)

iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday’s Pre-Market Session – Absci (NASDAQ:ABSI), Amazon.com (NASDAQ:AMZN)

U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Friday.

Shares of iRobot Corporation IRBT shares fell sharply in today’s pre-market trading.

The European Union’s competition watchdog is poised to reject Amazon.com Inc’s AMZN ambitious $1.7-billion acquisition of iRobot, The Wall Street Journal reported, citing sources close to the matter.

iRobot shares dipped 35.8% to $15.16 in pre-market trading.

Here are some big stocks recording losses in today’s pre-market trading session.

  • AST SpaceMobile, Inc. ASTS shares tumbled 18.5% to $3.39 in pre-market trading. AST SpaceMobile announced a $100 million offering of common stock. The company also announced a strategic investment from AT&T Inc T, Alphabet Inc GOOG GOOGL and Vodafone.
  • MorphoSys AG MOR shares declined 10.7% to $9.14 after falling 6% on Wednesday. Morgan Stanley analyst James Quigley, on Tuesday, downgraded MorphoSys from Overweight to Equal-Weight.
  • Absci Corporation ABSI shares fell 5.8% to $3.41 in pre-market trading. Absci recently appointed seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of Absci’s Scientific Advisory Board.
  • Diversified Energy Company PLC DEC shares declined 4.2% to $12.00 in pre-market trading.
  • XPeng Inc. XPEV shares fell 3.9% to $9.49 in pre-market trading after declining over 2% on Thursday.
  • Chegg, Inc. CHGG shares fell 3.7% to $9.69 in pre-market trading. Goldman Sachs analyst Eric Sheridan downgraded Chegg from Neutral to Sell and lowered the price target from $10 to $8.
  • Arcutis Biotherapeutics, Inc. ARQT shares fell 3.1% to $3.17 in pre-market trading. Arcutis Canada recently announced Health Canada acceptance of the supplement to a new drug submission for Roflumilast Foam 0.3% for seborrheic dermatitis in individuals 9 years of age and older.


Now Read This: Investor Sentiment Increases Following Economic Reports; Dow Jumps Over 200 Points

Don’t forget to check out our premarket coverage here